Related Experiment Video
Updated: Jun 28, 2026

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
Published on: October 25, 2024
YAZ and the novel progestin drospirenone
1Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. mishell@usc.edu
Drospirenone-containing oral contraceptives, including YAZ (drospirenone/20EE-24/4), offer effective contraception and a favorable safety profile. Studies show no increased risk of hyperkalemia or thromboembolic events compared to other progestins.
Area of Science:
- Pharmacology
- Gynecology
- Endocrinology
Background:
- Drospirenone is a progestin with antimineralocorticoid and antiandrogenic properties.
- Combination oral contraceptives (COCs) are widely used for birth control.
- Newer formulations aim to optimize efficacy and safety with lower estrogen doses and altered regimens.
Purpose of the Study:
- To evaluate the safety and efficacy of drospirenone-containing COCs, specifically drospirenone/20EE-24/4 (YAZ).
- To assess the risk of hyperkalemia and thromboembolic events associated with drospirenone/30EE.
- To highlight the unique indications of drospirenone/20EE-24/4.
Main Methods:
- Review of existing literature and noninterventional studies.
- Comparison of safety data between drospirenone-containing COCs and those with other progestins.
- Analysis of efficacy and safety profiles for drospirenone/20EE-24/4.
Main Results:
- Drospirenone/30EE (Yasmin) and drospirenone/20EE-24/4 (YAZ) provide effective contraception with a good safety profile.
- Noninterventional studies found no increased risk of hyperkalemia or thromboembolic events with drospirenone-containing COCs.
- Drospirenone/20EE-24/4 offers a low-dose ethinyl estradiol option with a shortened hormone-free interval.
Conclusions:
- Drospirenone-containing COCs, including YAZ, are safe and effective contraceptive options.
- The safety profile is comparable to COCs containing other progestins.
- Drospirenone/20EE-24/4 is indicated for contraception, premenstrual dysphoric disorder, and moderate acne.
Related Concept Videos
Birth Control Methods
Intrauterine Drug Delivery Systems
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...